Streetbeat News

ENVB

Enveric Biosciences, Inc.

https://www.enveric.com

Industry

Biotechnology

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Open

0.35

Mkt cap

3.2M

Volume

103K

High

0.35

P/E Ratio

-0.15

52-wk high

2.92

Low

0.34

Div yield

N/A

52-wk low

0.33

Several healthcare stocks experienced significant movement in Thursday's after-market session. Regulus Therapeutics, SeqLL, bioAffinity Technologies, Enveric Biosciences, Blue Water Biotech, and China Pharma Holding saw gains, while Baudax Bio, Surrozen, TransCode Therapeutics, IGC Pharma, Taysha Gene Therapies, and TRACON Pharma experienced losses.

Portfolio Pulse from Benzinga Insights

September 21, 2023 | 9:31 pm

Enveric Biosciences (NASDAQ:ENVB) has been granted a new patent by the U.S. Patent and Trademark Office (USPTO) for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301. The patent provides Enveric with IP rights for novel compositions and pharmaceutical drug formulations for a family of carboxylated derivatives of tryptamine-based drug candidates. The company expects the patent to add value to its EVM301 compounds series, currently undergoing lead optimization and preclinical characterization.

Portfolio Pulse from Lara Goldstein

September 21, 2023 | 4:00 am

Enveric Biosciences (NASDAQ:ENVB) has been granted a new U.S. patent for its EVM301 Series of drug candidates, which are carboxylated psilocybin derivatives aimed at treating mental health disorders. The patent covers novel compositions and pharmaceutical drug formulations, and is expected to strengthen and add value to Enveric's EVM301 Series. The company's CEO believes this could greatly enhance the commercial opportunity of EVM301 Series-based therapies.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 12:06 pm

Insiders at Eyenovia, Inc. (EYEN), Enveric Biosciences, Inc. (ENVB), and Porch Group, Inc. (PRCH) have recently acquired shares, indicating their confidence in the companies' prospects. EYEN's CEO bought 2,537 shares at an average price of $1.70, following a $12 million registered direct offering. ENVB's Director purchased 1,000 shares at an average price of $2.14, after the company filed a provisional patent application for AI-based computational methods. PRCH's Director, CEO, Chairman, and Founder acquired 86,373 shares at an average price of $0.83, despite the company posting a wider-than-expected quarterly loss.

Portfolio Pulse from Lisa Levin

September 20, 2023 | 11:58 am

The article discusses recent developments in the field of psychedelic medicine, including new data from MAPS PBC's Phase 3 clinical study of MDMA-assisted therapy for PTSD, a study suggesting that combining MDMA with psilocybin or LSD could reduce difficult trips, and the House Rules Committee's vote on psychedelics amendments. It also mentions Scotland's approval of a pilot safer drug consumption site, and various milestones in the psychedelic drugs market. The article also provides an update on the performance of the AdvisorShares Psychedelics ETF (PSIL) and several psychedelic stocks.

Portfolio Pulse from Lara Goldstein

September 18, 2023 | 10:06 pm

The Usona Institute has shared positive results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for adults with Major Depressive Disorder. COMPASS Pathways (NASDAQ:CMPS) has also shared results from research on its novel AI technologies to support proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression. In the UK, drug policy reform is underway, with a report urging the reclassification of psilocybin mushrooms and other psychedelics to Schedule 2. Several US states are also moving reform bills concerning the study or legalization of psychedelic substances for therapeutic purposes. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.79 on September 5, recovering from the prior week’s $1.65.

Portfolio Pulse from Lara Goldstein

September 11, 2023 | 1:34 pm

Enveric Biosciences has filed a provisional patent application for AI-based computational methods for identifying and optimizing novel tryptamine derivatives. This move could potentially lead to the development of new therapeutic solutions.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 12:06 pm

Several mergers and acquisitions have been announced in the psychedelics sector. Cybin (NYSE:CYBN) is acquiring Small Pharma (OTC:DMTTF), Silo Wellness (OTC:SILFF) is buying NUGL Inc./Kaya Group (OTC:NUGL), and Mindset Pharma (OTC:MSSTF) is being acquired by Otsuka America Inc., part of Otsuka Holdings (OTC:OTSKF). Additionally, Psyched Wellness (OTC:PSYCF) is set to receive $7.5M in financing. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has seen a slight increase in its share price.

Portfolio Pulse from Lara Goldstein

September 05, 2023 | 2:08 pm

Enveric Biosciences (NASDAQ:ENVB) has been granted a new U.S. patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives, which includes EB-373, a new chemical entity psilocin prodrug. The patent provides Enveric with intellectual property rights for compositions and methods for tryptamine-derived prodrugs. This strengthens Enveric's intellectual property portfolio and distinguishes its tryptamine-based prodrugs from similar compounds being developed for the treatment of mental health disorders.

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 12:03 pm

A recent study published in the Journal of the American Medical Association suggests that a single dose of psilocybin, a psychedelic compound produced by certain types of mushrooms, may have lasting benefits for people with major depressive disorder. The study adds to the growing body of evidence supporting the potential efficacy of psilocybin for depression treatment.

Portfolio Pulse from Happy Mohamed

August 31, 2023 | 3:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.